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oRIGINAL ARTICLE
Purpose: XL647 is an oral small-molecule inhibitor of multiple 
receptor tyrosine kinases, including endothelial growth factor recep-
tor (EGFR), vascular endothelial growth factor receptor 2, HER2 
and Ephrin type-B receptor 4 (EphB4). We undertook an open-label, 
multi-institutional Phase II study to investigate the efficacy and safety 
of XL647 in treatment-naive non–small-cell lung cancer patients 
clinically enriched for the presence of EGFR mutations.
Methods: Eligibility included patients with advanced-stage treat-
ment-naive lung adenocarcinoma with a known sensitizing mutation 
of EGFR or patients with at least one of the following criteria: being 
Asian, female, or having minimal or no smoking history. Two dosing 
schedules were evaluated; in the “intermittent 5 & 9 dosing” cohort, 
XL647 350 mg for 5 days every 14 days was given; and in the “daily 
dosing” cohort, XL647 300 mg daily for 28 days was administered. 
Tumor EGFR mutation status was determined on available tissue. 
The primary end point was confirmed objective response rate.
Results: Forty-one patients were treated on the intermittent 5 & 
9 dosing- and 14 on the daily-dosing schedule. The majority of patients 
were eligible on the basis of smoking history. The response rate and 
progression-free survival for the two schedules combined were 20% 
and 5.3 months (90% confidence interval, 3.7–6.7), respectively. 
Thirty-eight patients (69%) had material available for mutation testing 
and 14 EGFR-sensitizing mutations were detected. The response rate 
and progression-free survival for EGFR-mutation–positive patients 
were 57% (8/14) and 9.3 months (90% confidence interval, 5.5–11.7). 
The toxicities were comparable between the two schedules; the most 
common adverse effects being diarrhea, nausea, and fatigue.
Conclusions: XL647 administered on an intermittent or daily-dos-
ing schedule demonstrated antitumor activity in patients with EGFR-
activating mutations. The adverse-event profile was similar for the 
two dosing schedules.
Key Words: EGFR-sensitizing mutation, EGFR-resistance mutation, 
Tyrosine kinase inhibitor, Acquired resistance, Molecular analysis.
(J Thorac Oncol. 2012;7: 856–865)
Somatic EGFR mutations in patients with non–small-cell lung cancer (NSCLC) have been identified as the basis of 
sensitivity to the endothelial growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib.1–3 
The most prevalent mutations consist of deletions of exon 
19 and a point mutation (L858R) in exon 21, which together 
comprise over 90% of all EGFR kinase domain mutations.1–3 
Unfortunately, patients with EGFR-mutant NSCLC inevi-
tably develop progression of disease within a median of 9 to 
11 months4–6 while receiving erlotinib or gefitinib, which has 
been described as “acquired resistance”.7 The most common 
mechanism of acquired resistance is caused by the develop-
ment of the T790M mutation in exon 20 of EGFR in nearly 
50% of patients, whereas 10% of the patients have amplifica-
tion of the oncogene MET as a means of resistance.8–14
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Targeting other cellular processes while simultane-
ously inhibiting the EGFR pathway may overcome resistance 
mechanisms and lead to improved outcomes. In particular, 
the vascular endothelial growth factor receptor (VEGFR) 
and EGFR signaling cascades share common downstream 
pathways.15 Activation of EGFR by either endothelial growth 
factor or transforming growth factor- increases the produc-
tion of VEGF in human cancer cells, and inhibition of EGFR 
downregulates vascular endothelial growth factor (VEGF).16–19 
Thus far, simultaneous inhibition of EGFR and VEGF in 
patients has demonstrated variable activity. Patients receiv-
ing both erlotinib and bevacizumab after first-line platinum 
doublet and bevacizumab treatment, were noted to have a sig-
nificant improvement in progression-free survival (PFS) and 
a nonsignificant benefit in overall survival (oS), compared to 
those receiving bevacizumab alone in the Phase III ATLAS 
study.20 The combination of erlotinib with bevacizumab in the 
second-line treatment of patients with NSCLC did not demon-
strate a benefit in oS compared to erlotinib alone in the Phase 
III BeTa trial; yet those patients treated with both erlotinib 
and bevacizumab had improved overall response and PFS.21 
Vandetanib, an oral small-molecule TKI that targets EGFR, 
all three VEGF receptors, and rearranged during transfection 
(RET) tyrosine kinases, has led to improvements in response 
rates, yet oS end points have not been met.22,23
XL647 is a “second-generation” small-molecule, 
reversible ATP-competitive inhibitor of EGFR (IC
50
 0.3 nM), 
HER2/ErbB2 (IC
50
 16 nM), VEGFR-2/KDR (IC
50
 1.5 nM), 
and EphB4 (IC
50
 1.4 nM).24 When compared to other small 
molecules, XL647 has a potency similar to that of BIBW2992, 
an irreversible dual EGFR and human epidermal growth fac-
tor receptor-2 (HER2) inhibitor, for inhibiting EGFR (IC
50
 0.4 
nM) and HER2 (IC
50
 of 14 nM), and also to that of AZD2171, 
a pan-VEGF receptor inhibitor, for inhibiting VEGFR-2/
KDR (IC
50
 < 1 nM), yet is more active than vandetanib versus 
VEGFR-2/KDR (IC
50
 40 nM) and EGFR (IC
50
 500 nM).25–27 
XL647 inhibits cellular proliferation and EGFR-pathway acti-
vation in the erlotinib-resistant H1975 cell line that harbors 
a double mutation (L858R and T790M) in EGFR. In vivo 
efficacy studies show that XL647 substantially inhibited the 
growth of H1975 xenograft tumors, and reduced both tumor 
EGFR signaling and tumor vessel density. Further, XL647 
demonstrated an inhibitory effect on tumor cell growth and 
tumor vasculature in both EGFR mutant xenografts and MDA-
MB-231 xenografts that highly express VEGF.24
on the basis of encouraging preclinical activity, particu-
larly in the H1975 cell line,24 and antitumor efficacy in NSCLC 
in the Phase I study,28 we undertook this first-line trial in patients 
with metastatic lung adenocarcinoma whose tumors harbored a 
known sensitizing mutation of EGFR or in patients with clini-
cal characteristics (Asian race, female, minimal smoking his-
tory, or no smoking history) likely to respond to EGFR TKIs.1,29 
Here, two different dosing schedules of XL647 were evaluated 
sequentially. An “intermittent 5 & 9 dosing” cohort was first 
accrued, in which patients were dosed for 5 consecutive days 
at 350 mg daily every 14 days, as this was the schedule evalu-
ated in the first Phase I study with this agent.28 Concomitantly, 
Phase I and Phase II data emerged using daily dosing of XL647 
at 300 mg daily for 28 days, showing a similar safety profile 
to the intermittent dosing schedule, while possibly yielding a 
twofold increase in average exposure over 28 days.30,31 In an 
attempt to further enhance the efficacy on EGFR and VEGFR2 




All patients had treatment-naive, advanced-stage adeno-
carcinoma of the lung. A documented mutation of the EGFR 
receptor was needed or patients had to have met at least one 
of the following criteria: Asian race, female, or minimal (<15 
pack-years and no smoking history within the last 25 years) or 
no smoking history. Inclusion required Eastern Cooperative 
oncology Group performance status of 0 or 1, and measurable 
disease as per Response Evaluation Criteria in Solid Tumors 
(RECIST 1.0).32 Patients were excluded if they had progres-
sive, symptomatic, or hemorrhagic brain or leptomeningeal 
metastases. Cardiac conditions that precluded entry to the study 
included: corrected QT interval (QTc) of more than 0.46 sec-
onds; family history of congenital long QT syndrome or unex-
plained sudden death; sustained ventricular arrhythmias; left 
bundle branch block; obligate pacemaker; significant bradycar-
dia; uncontrolled hypertension; and significant heart disease.
This trial was reviewed and approved by the Institutional 
Review Board of each center; all patients provided written 
informed consent. Data were collected and analyzed cen-
trally at Exelixis, with direct inspection and review by all lead 
investigators.
Treatment
Patients were treated with single-agent oral XL647 in 
two sequential cohorts evaluating different dosing schedules. 
In the intermittent 5 & 9 dosing cohort, patients received 
XL647 at a dose of 350 mg for 5 days every 14 days.28 In 
the daily-dosing cohort, patients received XL647 at a dose of 
300 mg daily for 28 days.30 XL647 was continued until the 
development of unacceptable toxicity or progression of dis-
ease. Grade 3 or 4 toxicities believed to be possibly related to 
XL647 were managed with dose interruptions until resolution 
to grade 1 or less, or baseline values. Upon improvement of 
such toxicities, the dose of XL647 was reduced by 50 mg/day; 
two dose reductions were permitted.
Evaluation
Patients were evaluated on days 1 and 5 of the inter-
mittent 5 & 9 dosing schedule and days 1 and 15 of the 
daily-dosing for the first 2 months and monthly thereafter. 
All toxicities were graded using National Cancer Institute 
Common Terminology Criteria for Adverse Events version 
3.0. Computed tomography scans of all sites of measurable 
disease were obtained at baseline and approximately every 
8 weeks thereafter. Responses were determined using RECIST 
1.0.32 All imaging studies were reviewed by investigators or 
independent radiologists at each site. A radiological review 
was conducted by the sponsor to verify response assessments. 
This review confirmed that tumor response was valid and 
complied with RECIST 1.0.32
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Patients who received one dose of the study drug were 
evaluable for toxicity. Patients were considered evaluable for 
response if they had received at least one dose of study drug 
and had a baseline and at least one post baseline-efficacy 
tumor assessment.
Genotyping of Tumor
DNA from available tumor samples was analyzed for the 
presence of EGFR mutations at different institutions using stan-
dard methods (direct sequencing, polymerase chain reaction-
single strand conformation polymorphism,33 or polymerase 
chain reaction-restriction fragment length polymorphism).34
Archival tumor samples from before the initiation of 
XL647 were analyzed for EGFR and KRAS mutations when 
available. However in three cases, tumor samples became avail-
able only after the completion of XL647 dosage, and the muta-
tion data of these patients are also included in our analysis.
Pharmacokinetics and Pharmacokinetic 
Analysis
Plasma pharmacokinetic samples were collected at 
predose and 0.5, 1, 2, 4, and 8 hours postdose on day 1, and 
at predose and 4 hours postdose on days 5, 19, 33, and 47 
and monthly thereafter for the intermittent 5 & 9 dosing regi-
men. For the daily-dosing regimen, samples were collected at 
predose and 4 hours postdose on days 1, 15, 29, and 43 and 
monthly thereafter beginning at week 8. At each time point, 
blood was collected into tubes with potassium ethylenedi-
aminetetraacetic acid as anticoagulant, and centrifuged to 
generate plasma, which was frozen at −70°C until analysis. 
The concentration of XL647 was quantitated with a validated 
LC-MS/MS assay, with a linear range of 1 to 500 ng/ml, using 
50 μl of sample.
Day-1 maximum XL647 plasma concentration (C
max
) 




) were extracted by visual inspection. For 
more comprehensive analysis of this dataset obtained via lim-
ited sampling design with multiday pharmacokinetic sampling, 
we chose the compartmental method population approach. We 
utilized ADAPT 5 software for pharmacokinetic/pharmacody-
namic systems analysis.35 The maximum likelihood option in 
ADAPT 5 was used for all estimations, and parameters were 
assumed to be log-normally distributed. Because the data for 
the daily schedule extended over a long period, data from later 
cycles were moved to earlier time points to facilitate database 
generation. No data were moved before day 15 to ensure that 
any accumulation of drug would have reached steady state 
(assured by day 15 concentrations generally being similar to 
later concentrations). Initial population mean estimates were 
derived from Naïve Pooled Data analysis. Next, an Iterated 
Two-Stage analysis yielded estimates of population param-
eter values, which were then utilized as starting points for a 
Maximum Likelihood solution via EM Method. We assumed a 
one-compartment, open, linear model with first-order absorp-
tion. To address flip-flop kinetic behavior, we forced Ka > Ke. 
Initially, data were analyzed by administration schedule. As 
expected, initial results showed no evidence of large differences 
in parameter values between schedules (within 30%), and all 
currently presented results are based on the complete data set. 
After defining stable estimates for the population pharmacoki-
netic parameters, our limited validation consisted of changing 
the value of an individual population pharmacokinetic param-
eter (volume [Vd/F], elimination rate [K
10
], and absorption rate 
[K
a
]) twofold up or down. Final values obtained after this exer-
cise were compared with those of the initial model.
Statistical comparisons of concentration values were 
performed using SPSS 17.0 for Windows (SPSS Inc., Chicago, 
IL). Values were compared with a two-tailed, paired exact 
Wilcoxon signed rank test, where a p< 0.05 was considered 
significant.
Statistical Analysis
The primary objectives were to determine the overall 
response rate (complete and partial response), and evaluate 
the safety and tolerability of XL647. Secondary end points 
included PFS and oS.
A Simon two-stage design was used for the intermit-
tent 5 & 9 dosing cohort, with stage 1 enrolling 15 evaluable 
patients. If there was 1 or more responders out of 15 evalu-
able patients, additional subjects would be accrued to enroll at 
least 37 evaluable subjects. If a total of two or more confirmed 
responses were observed in the intermittent 5 & 9 dosing 
cohort, then this XL647 schedule would be considered as hav-
ing demonstrated antitumor activity. If the true response rate 
was 11% or greater, there would be at least an 80% probability 
of concluding that XL647 has adequate efficacy.
For the daily-dosing cohort, a single-stage design was 
used, which anticipated enrolling a total of 24 patients to ensure 
that 21 were evaluable. If at least four confirmed responses were 
noted, then the XL647 daily-dose regimen would be considered 
as having demonstrated antitumor activity. If the true response 
rate was 25% or greater, there would be at least an 80.8% prob-
ability of concluding that XL647 has adequate efficacy.
The Kaplan-Meier method was used to estimate PFS 
and oS. Patients were censored at date of last contact or analy-
sis cutoff date for both PFS and oS.
EGFR-mutant tumors were correlated with response, 
PFS, and oS in an exploratory analysis.
RESULTS
Baseline Characteristics
Between october 12, 2006 and November 24, 2008, 
 41 subjects were enrolled in the intermittent 5 & 9 dosing cohort 
and 14 patients in the daily-dosing group. Accrual in the daily-
dosing cohort began once enrollment in the intermittent 5 & 
9 dosing group was completed. As a result of slow enrollment 
in the daily-dosing cohort, the study was closed before reach-
ing the anticipated accrual of 21 evaluable patients. Baseline 
characteristics for patients by cohort are listed in Table 1. 
of note, 53% of the patients were never smokers and 29% had 
a minimal smoking history; thus, the majority of the patients 
were deemed eligible based on smoking criterion.
Treatment
All patients received at least one cycle of XL647; the 
median number of cycles was nine (range 2–45) and three 
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(range, 1–23) in the intermittent 5 & 9 dosing cohort and the 
daily-dosing group, respectively. Patients remained on XL647 
for a median of 121 days (range, 9–621 days) and 144 days 
(range, 15–302 days) in the intermittent 5 & 9 dosing group 
and the daily-dosing cohort, respectively.
Toxicity
Table 2 lists the most common treatment-related tox-
icities. All patients enrolled in each cohort were evaluable for 
toxicity (intermittent 5 & 9 dosing N=41; daily dosing N=14).
In the intermittent 5 & 9 dosing cohort, four patients 
required a dose reduction for toxicity (10%), two for grade 3 
QTc prolongation, and two for grade 3 diarrhea. Four patients 
in this cohort each experienced a serious adverse event thought 
to be related to XL647: grade 3 pneumonia (XL647 dosing 
interrupted); grade 3 gastrointestinal bleed (XL647 discontin-
ued); grade 3 QTc prolongation (XL647 dose reduced); and 
grade 1 rash (drug continued). In addition to the one patient 
described in whom XL647 was discontinued, the drug was 
stopped in an additional subject for grade 2 onychomadesis 
after having been on study for 102 days. one patient died 
while on study secondary to acute respiratory distress syn-
drome not related to XL647.
Four patients (29%) of the 14 in the daily-dosing cohort 
required a dose reduction; one each for grade 3 QTc prolon-
gation, diarrhea, and rash, and one for grade 1 gastrointesti-
nal discomfort. Grade 3 gastrointestinal bleed in one patient 
was attributed to XL647 and led to its discontinuation. XL647 
was stopped in an additional patient who developed grade 2 
increased creatinine and hyperkalemia. There were no treat-
ment-related deaths; one patient died during the seventh 
month on study secondary to underlying lung cancer, possibly 
complicated by pneumonia.
Importantly, hypertension was not observed in any of 
the patients receiving daily XL647, and was noted only in one 
subject in the intermittent 5 & 9 cohort (grade 1).
Efficacy
Thirty-nine patients in the intermittent 5 & 9 dosing 
cohort and 12 patients in the daily-dosing cohort were evaluable 
for efficacy. of the four patients who were not evaluable for effi-
cacy, two experienced early adverse events of grade 3  or greater 
levels not considered related to XL647 (grade 3 deep venous 
thrombosis, N=1, at day 8; grade 4 pleural effusion, N=1, at day 
14) and developed rapid clinical deterioration, one withdrew 
consent, and one experienced grade 3  gastrointestinal bleed 
related to XL647. As these patients did not undergo imaging 
reevaluation, they were deemed inevaluable for efficacy.
Ten patients exhibited a partial response to XL647 from 
both cohorts combined (response rate 19.6%, 90% confidence 
interval [CI], 11%–31%), (Tables 3 and 4 and Fig. 1). Median 
PFS for the 51 evaluable patients was 5.3 months (90% CI, 
3.7–6.7). Median oS for all 55 treated patients was 19.3 
months (90% CI, 18.4–23.3).
Molecular Characteristics
Although not mandated by protocol, 38 out of 55 patients 
(69%) provided tumor samples for mutation testing (see 
Table 1). Results were not available for all patients before ini-
tiating therapy on XL647; some tumor samples were analyzed 
retrospectively as tissue became available. Three patients 
underwent biopsy after completing therapy with XL647.
In this clinically enriched population, EGFR-sensitizing 
mutations were found in tissue samples of 14 subjects (exon 
19 deletion, N=9; exon 21 L858R and N=5), or 37% (14 
of 38 available samples). one of the patients with an exon 
19 deletion underwent biopsy upon disease progression after 
6 months of treatment with XL647, and at that time, also was 
found to have an exon 20 T790M mutation. This patient was in 
the daily-dosing cohort, required two dose reductions second-
ary to grade 3 rash, and although the first post-XL647 treat-
ment scan documented partial response, it was not confirmed. 
The tumors of two additional patients harbored rarer EGFR 
mutations (exon 19 insertion, N=1; exon 20 ins770GRV, N=1). 
KRAS G12V and G12A mutations were found in the tumors of 
two additional patients.
TABLE 1. Baseline Patient Characteristics by Cohort
Characteristic
Intermittent 5 & 9 
Dosing (N=41) Daily Dosing (N=14)
No. No.
Sex
 Male 11 2
 Female 30 12
Age
 Median 66.2 65.7
 Range 45–86 42–80
ECoG Performance Status
 0 16 5
 1 25 9
Race/Ethnicity
 White 36 11





 Never 20 9
 ≤15 pack-years 14 2
 >15 pack-years 7 3
Tumor Mutation Status
 EGFR exon 19 del 6 3
 EGFR exon 21 L858R 3 2
 EGFR exon 19 
insertion (18bp)
0 1
 EGFR exon 20 
ins770GRV
0 1
 KRAS 2 0
 EGFR and KRAS 
wild-type
18 2
 Unknowna 12 5
aUnknown includes inadequate tissue (n=3) or tissue unavailable and/or no patient 
consent  (n=14).
ECoG, Eastern Cooperative oncology Group; EGFR, endothelial growth factor 
receptor.
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TABLE 2. Related Adverse Events
Adverse Event§
Any Grade 1 Grade 2 Grade 3
N (%) N (%) N (%) N (%)
Intermittent 5 & 9 dosing  
  (N=41)
 Diarrhea 33 (80) 24 (59) 7 (17) 2 (5)
 Rash 26 (63) 22 (54) 4 (10) 0 (0)
 Fatigue 24 (59) 18 (44) 5 (12) 1 (2)
 Nausea 17 (41) 17 (41) 0 (0) 0 (0)
 Pruritus 9 (22) 7 (17) 2 (5) 0 (0)
 Dry skin 6 (15) 5 (12) 1 (2) 0 (0)
 Dysgeusia 5 (12) 4 (10) 1 (2) 0 (0)
 Mucosal inflammation 4 (10) 3 (7) 1 (2) 0 (0)
 QTc prolongation 4 (10) 2 (5) 0 (0) 2 (5)
 Dry mouth 3 (7) 3 (7) 0 (0) 0 (0)
 Vomiting 3 (7) 2 (5) 1 (2) 0 (0)
Daily dosing (N=14)
 Diarrhea 6 (43) 3 (21) 1 (7) 2 (14)
 Nausea 4 (29) 3 (21) 1 (7) 0 (0)
 Fatigue 2 (14) 0 (0) 2 (14) 0 (0)
 Anorexia 2 (14) 1 (7) 1 (7) 0 (0)
 Rash 3 (21) 2 (14) 0 (0) 1 (7)
 QTc Prolongation 1 (7) 0 (0) 0 (0) 1 (7)
TABLE 3. Efficacy by Cohort for Advanced NSCLC Patients Treated with XL647
Best Overall Response Intermittent 5 & 9 Dosing (N=39) Daily Dosing (N=12) Cohorts Combined (N=51)
Confirmed complete response 0 (0%) 0 (0%) 0 (0%)
Confirmed partial response 8 (21%) 2 (17%) 10 (20%)
objective response ratea 8 (21%) 2 (17%) 10 (20%)
[90% CI, 11%–34%] [90% CI, 3%–44%] [90% CI, 11%–31%]
Stable disease 20 (51%) 8 (67%) 28 (55%)
Progressive disease 11 (28%) 2 (17%) 13 (25%)
aobjective response rate is complete plus partial response.
NSCLC, non–small-cell lung cancer; CI, confidence interval.
EGFR-sensitizing mutations (exon 19 deletion and 
exon 21 L858R mutation) were noted in the tumors of eight 
of the 10 patients (80%) with a partial response to XL647, 
(Table 4). The additional two patients who had a response to 
XL647 were both female, one was a never-smoker and the 
other a former light smoker (6-pack-year history). The tumors 
of both of these patients were tested and not found to harbor 
an EGFR or KRAS mutation. Median PFS of the 14 patients 
whose tumors harbored an EGFR-sensitizing mutation was 
9.3 months (90% CI, 5.5–11.7 months) compared to 3.6 
months (90% CI, 2–5 months) for those without such a muta-
tion, p=0.003 (Fig. 2A). Similarly, median oS (Fig. 2B) was 
better for patients with exon 19 deletion or L858R mutation in 
their tumors compared to those without such mutations (22.5 
months [90% CI, 19.3 months to not yet reached] versus18.4 
months [90% CI, 13.6–19.6 months], p = 0.05).
Patients whose tumors harbored sensitizing EGFR muta-
tions demonstrated a partial response (8/14, 57%) or stable 
disease (6/14, 43%) to XL647 (Table 4). of the six patients with 
stable disease, only one demonstrated tumor growth of 12%, 
whereas the remainder had disease reduction between 9% and 
59%. These six patients were treated with XL647 between 4 
and 11 months. Patients with the rarer EGFR mutations (exon 
19 insertion, N=1; exon 20 ins770GRV, N=1) in their tumors did 
not have a response to XL647. Stable disease and progression 
of disease were noted in patients whose tumors harbored KRAS 
G12A mutation and KRAS G12V mutation, respectively. only 
two patients whose tumors did not contain an EGFR-sensitizing 
mutation had a partial response to XL647 (2/24, 8%).
The median PFS was 9.5 months (90% CI, 3.7–18.2 
months) in patients whose tumors harbored EGFR exon 19 
deletion compared to 7.1 months (90% CI, 3.7 months to not 
yet reached) in those with exon 21 L858R mutation. Median 
oS has not been reached for those patients with L858R muta-
tion in their tumors, and was 21.8 months for those with 19 
deletion (90% CI, 19–23 months), Table 4.
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TABLE 4. Outcomes for XL647 According to EGFR Mutations Detected
No. Evaluable




Months (90% CI)PR (%) SD (%) PD (%)
All Patients 51 10 (20) 28 (55) 13 (25) 5 (4–7) 19 (18–23)
No. activating EGFR mutations 37 2 (5) 22 (43) 13 (35) 4 (2–5) 18 (14–20)
Exon 19 deletion 9 6 (67) 3 (33) 10 (4–18) 22 (19–23)
Exon 21 L858R 5 2 (40) 3 (60) 7 (4 to not reached) Not reached
aAll 55 treated patients.
EGFR, endothelial growth factor receptor; PR, partial response; SD, stable disease; PD, progression of disease.
Pharmacokinetics
of the patients enrolled, 19 and 13 had pharmacokinetic 
(PK) data on the intermittent 5 & 9 dosing schedule and daily-





 for the intermittent 5 & 9 schedule and the concentrations 
at 4 hours for both schedules, as patients on the daily sched-
ule were only sampled at 4 hours postdose. As expected, the 
4-hour concentration values did not differ between schedules.
A consequence of using the limited sampling schedule, 
combined with the late T
max
 of XL647 and absence of termi-
nal phase plasma data, is that the data were not able to prop-
erly inform K
10
 of XL647. As a result, estimates of terminal 
half-life and Vd/F were unreliable. This was evidenced by the 
convergence of our validation models to different population 
parameter values for Vd/F and K
10
.
However, the steady-state concentrations at multiple 
time points for weeks during dosing did allow good estima-
tion of apparent clearance (Cl/F). This is because the average 
steady-state concentration is a function of Cl/F, dose, and dose 
interval, not Vd/F, nor half-life. our validation models consis-
tently converged to population parameter values for Cl/F that 
were within 2% of the initial estimates, whereas the population 
mean values for Ka and Vd/F varied between −45% to +31%. 
The population mean Cl/F was 28.3 liter/hour with a popula-
tion standard deviation of 8.1 liter/hour. Representative exam-
ples of concentration versus time profiles are shown in Figure 
3. In two patients on the daily schedule, 30-day post-last dose 
PK samples were obtained. Concentrations had decreased to 
9.1% and 5.5% respectively, of the concentration at the last day 
of dosing, which corresponds to a half-life of 7.2 to 8.7 days.
DISCUSSION
This Phase II study of XL647 was designed to assess 
the efficacy and safety of this TKI in patients with advanced, 
untreated NSCLC phenotypically enriched for EGFR-
sensitizing mutations (Asian, female, or minimal or no smok-
ing history)1,29 or whose tumors were known to harbor an 
EGFR exon 19 deletion or EGFR exon 21 L858R mutation. 
XL647 was well tolerated in this patient population. We found 
a 20% overall response rate in evaluable patients treated with 
XL647. Responses most often were noted in patients with 
sensitizing EGFR mutations, emphasizing the importance of 
mutation analyses in patients receiving TKIs.
Two dosing schedules were evaluated sequentially in this 
study: intermittent 5 & 9 dosing and daily dosing. When the 
protocol originally was designed, Phase I data were available 
for the intermittent schedule with 5 days of treatment every 
14 days.28 During the course of this Phase II trial, results from 
Phase I and Phase II studies showed that a flat daily dose of 
300 mg resulted in an average steady-state plasma concentra-
tion similar to the average concentration over 24 hours after 
the last dose when XL647 was administered intermittently.30 
Given the similar safety profile of the daily-dosing and the 
intermittent-dosing schedules, and the possibility of yielding 
a twofold increase in average exposure over 28 days,30,31 which 
could further enhance the efficacy on EGFR and VEGFR-2 
inhibition, a second cohort of patients was evaluated with the 
daily-dosing regimen.
The most common treatment-related adverse events 
seen with XL647 were grade 1 and grade 2 diarrhea, rash, 
nausea, and fatigue, as seen with the first-generation TKIs.4,5,36 
There were no grade 4 toxicities in either treatment sched-
ule cohorts. A dose reduction for toxicity was required in four 
patients in each cohort, and two patients in each cohort had 
the drug discontinued secondary to adverse events.
Hypertension was not observed in any of the patients 
receiving daily XL647 and was noted only in one subject 
in the intermittent 5 & 9 cohort (grade 1). Hypertension 
is a mechanism-based toxic effect of the VEGF signaling 
pathway inhibitors,37 the incidence of which has been noted 
to range between 17% and 72% for agents such as bevaci-
zumab, cediranib (AZD2171), vandetanib (ZD6474), afliber-
cept (VEGF-trap), and sunitinib.37 Although in vitro studies 
have shown that XL647 is similar to AZD2171 for inhibit-
ing VEGFR-2/KDR and more active than vandetanib versus 
VEGFR-2/KDR,26,27 the low frequency of hypertension noted 
here could be a result of the drug not achieving concentrations 
sufficient to inhibit VEGFR.
Previously, T
max
 of XL647 was reported to be between 4 
and 9 hours postdose, with steady-state concentrations being 
achieved within 15 days and elimination half-lives of 50 to 70 
hours.28,30 In the current study, we observed a T
max
 of 5.3 hours 
and steady-state levels achieved within 15 days. Apparent 
clearance was 28.3 liter/hour, and there is some suggestion 
that the terminal half-life is up to 8 days, or approximately 
200 hours, which is much longer than the previously reported 
half-life. Together, this raises the possibility of multicompart-
mental pharmacokinetic behavior with a second compartment 
revealing itself only at later times. The clinical relevance of 
such prolonged retention remains undefined, and more exten-
sive, well-designed pharmacokinetic studies would be required 
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FIGURE 1. Waterfall Plot. (A) The best calculated responses based on measurable lesions for evaluable patients, N=51. Here, 
50 evaluable patients represented as one patient had unequivocal progression of a nontarget pleural effusion that obscured 
measurement of underlying target lesions. (B) The best calculated responses based on measurable lesions for all patients 
with EGFR-mutant tumors, N=14. *Patients with unconfirmed partial response. EGFR, endothelial growth factor receptor.
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to further define this behavior. our results show that the daily 
schedule results in a continuous exposure to XL647 concen-
trations that is comparable to those achieved during the last 
days of dosing on the intermittent schedule. The daily sched-
ule is, therefore, expected to result in more durable target inhi-
bition, which should reduce the likelihood of development of 
resistant subclones, and from a patient adherence perspective, 
is preferable to the more complicated intermittent schedule.















5 & 9 (350 mg)
240 (125) 5.3 (1.9) 233 (130)
Daily (300 mg) — — 259 (299)
SD, standard deviation.
FIGURE 2. Kaplan-Meier curves for outcomes. (A) Progression-free survival for 51 evaluable patients, depending upon 
whether a sensitizing mutation was present or not in the tumor sample. (B) Overall survival for entire cohort of 55 
patients, depending upon whether sensitizing mutation was present or not in the tumor sample.
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This study began enrolling patients in March 2006, at 
which time we believed that administering EGFR TKIs to 
patients with characteristics associated with EGFR mutations 
would lead to increased responses.1,29 Since then we have learned 
that selection based on clinical criteria alone is inadequate. 
In the Iressa Pan-Asia Study (IPASS) in which patients were 
clinically selected to receive either gefitinib or chemotherapy 
first line,36 only 60% of adequate tumor specimens were found 
to harbor EGFR mutations, and those patients in the mutation-
negative subgroup did not benefit from gefitinib.36 Additional 
studies have demonstrated low mutation rates when using an 
enrichment strategy to predict for EGFR mutations.38,39 Here, 
our mutation rate was only 37%. These substantiate the need 
for definitive molecular testing and the presence of a genetic 
abnormality before treating patients with a targeted agent.
We found that patients with EGFR mutations had a 57% 
objective response rate and median PFS of 9.3 months when 
treated with XL647 first-line. These results are comparable 
to studies using erlotinib or gefitinib as first-line therapy in 
patients with EGFR mutations. In numerous Phase II studies of 
gefitinib or erlotinib, response rates were noted to be between 
55% and 91%, with PFS between 7.7 and 13.2 months. These 
results recently were confirmed in three Phase III studies.4–6
In summary, whereas first-line therapy with XL647 is min-
imally active in a phenotypically enriched population of patients 
with advanced NSCLC, it has activity in those with tumors har-
boring EGFR mutations comparable to erlotinib or gefitinib. The 
agent is well tolerated in the two dosing regimens evaluated.
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